Ann: ATH Annual General Meeting Presentation, page-22

As per my previous conversations with management, I reiterate that PBT2 is well and truly on the back burner. Like M says, better they focus on this one task with advancing ath434 so they have less chance of screwing that up and give it the best chance to succeed as possible.

the trading action in the US is annoying and painful to watch. The hopes of any rebound are met with continuous selling. Can’t know for sure who is doing this as I can only see regal and CS involvement in the Australian register, which as a whole is no more than 32% at this stage. I note the athe price now sits under 50% of the most recent ATM raise.

I think important price points are .032 which is where dr stamler has his options and bio life sciences average price at around .~038.

I have some spare cash aside to target anything at or under 28M EV Australian equivalent but with further sp languishing, the more I question whether management can deliver.

from an athe chart perspective, I think there will be a capitulation before heading higher due to an announcement. I’m not sure when or what it will be but I hope it will be something before the commencement of P2 To stem the bleeding. The thing that gets me is that a 10-30% decrease in price from here is still negligible to the potential. But the opportunity cost continues to be very painful. Any new buyer would be lucky to get in now at these prices as next year should see much more material information being released. I’ve had my timing wrong and all this time I could have bought in this coming Monday at a better average price I’m holding but I continue to believe at my own peril that sub .028 will be good buying. Hence why I will buy more if that happens.

this stock is not for the faint of heart, the impatient or those with high risk adversity, that’s for sure.

gltah and dyor